



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** office@baishideng.com  
<https://www.wjgnet.com>

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 90377

**Title:** Identification and validation of a new prognostic signature based on cancer-associated fibroblast-driven genes in breast cancer

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05430684

**Position:** Peer Reviewer

**Academic degree:** MD, MSc, PhD

**Professional title:** Consultant Physician-Scientist, Research Fellow

**Reviewer's Country/Territory:** Greece

**Author's Country/Territory:** China

**Manuscript submission date:** 2023-12-01

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2023-12-01 16:39

**Reviewer performed review:** 2023-12-03 11:38

**Review time:** 1 Day and 18 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation

<b>Scientific significance of the conclusion in this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS

I have studied the manuscript entitled "Identification and validation of a new prognostic signature based on cancer-associated fibroblast-driven genes in breast cancer" by Wu Z. et al. The manuscript is not novel. Nevertheless, it is well organized and the language used is of adequate quality. However, the authors are welcome to assess several queries before considering publication. Major issues: 1. The authors are welcome to discuss the findings of three recent and very relevant publications: i) Wang Y, et al. A novel signature based on cancer-associated fibroblast genes to predict prognosis, immune feature, and therapeutic response in breast cancer. Aging (Albany NY). 2023;15(9):3480-3497. doi: 10.18632/aging.204685. Epub 2023 May 4. PMID: 37142271; PMCID: PMC10449298, ii) Huang B, et al. Construction of a Matrix Cancer-Associated Fibroblast Signature Gene-Based Risk Prognostic Signature for Directing Immunotherapy in Patients with Breast Cancer Using Single-Cell Analysis and Machine Learning. Int J Mol Sci. 2023;24(17):13175. doi: 10.3390/ijms241713175. PMID: 37685980; PMCID: PMC10487765, and iii) Xu A, et al. Identification of prognostic cancer-associated fibroblast markers in luminal breast cancer using weighted gene co-expression network

analysis. *Front Oncol.* 2023 May 3;13:1191660. doi: 10.3389/fonc.2023.1191660. PMID: 37207166; PMCID: PMC10191114. 2. The authors are encouraged to update the references used, since the topic is rapidly gaining interest. As a paradigm, the following publications are referred: i) Avalle L, et al. STAT3 induces breast cancer growth via ANGPTL4, MMP13 and STC1 secretion by cancer associated fibroblasts. *Oncogene.* 2022;41(10):1456-1467. doi: 10.1038/s41388-021-02172-y. Epub 2022 Jan 18. PMID: 35042959, ii) Zeng H, et al. Cancer-associated fibroblasts facilitate premetastatic niche formation through lncRNA SNHG5-mediated angiogenesis and vascular permeability in breast cancer. *Theranostics.* 2022;12(17):7351-7370. doi: 10.7150/thno.74753. PMID: 36438499; PMCID: PMC9691361., iii) Fang WB, et al. Transcriptome analysis reveals differences in cell cycle, growth and migration related genes that distinguish fibroblasts derived from pre-invasive and invasive breast cancer. *Front Oncol.* 2023;13:1130911. doi: 10.3389/fonc.2023.1130911. PMID: 37091166; PMCID: PMC10118028. 3) Many figures are hardly readable; thus it is impossible to review the figures 2, 3, 5, 6, 7, 8, 10, 11, 14, S1, and S2. Therefore, the authors are kindly requested to provide figures of enhanced quality. Minor issues 1) The authors are requested to explicitly define overall survival. 2) The authors are kindly requested to explicitly comment on missing values and state whether they have imputed data. 3) The authors are kindly asked to provide a Supplementary Table with the detailed results of the LASSO analysis depicted in Figure 5A.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 90377

**Title:** Identification and validation of a new prognostic signature based on cancer-associated fibroblast-driven genes in breast cancer

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05244179

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** India

**Author's Country/Territory:** China

**Manuscript submission date:** 2023-12-01

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2023-12-01 17:39

**Reviewer performed review:** 2023-12-04 11:58

**Review time:** 2 Days and 18 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** office@baishideng.com  
**https://**www.wjgnet.com

<b>Scientific significance of the conclusion in this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS

1. Conclusion in abstract does not match the conclusion given in main text file. 2. What method has been employed in the present study to see prognosis in set of patients studied? The study is a retrospective study, there is no mention of disease free survival or recurrence and its correlation with the markers studied. SPECIFIC COMMENTS ARE MARKED IN DIFFERENT SECTIONS IN THE ATTACHED REVIEWED FILE.

## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 90377

**Title:** Identification and validation of a new prognostic signature based on cancer-associated fibroblast-driven genes in breast cancer

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05430684

**Position:** Peer Reviewer

**Academic degree:** MD, MSc, PhD

**Professional title:** Consultant Physician-Scientist, Research Fellow

**Reviewer's Country/Territory:** Greece

**Author's Country/Territory:** China

**Manuscript submission date:** 2023-12-01

**Reviewer chosen by:** Ji-Hong Liu

**Reviewer accepted review:** 2023-12-18 08:49

**Reviewer performed review:** 2023-12-18 09:24

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer</b>	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** office@baishideng.com  
**https://**www.wjgnet.com

statements

Conflicts-of-Interest: [ ] Yes [Y] No

#### **SPECIFIC COMMENTS TO AUTHORS**

I have studied the revised form of the manuscript entitled "Identification and validation of a new prognostic signature based on cancer-associated fibroblast-driven genes in breast cancer" by Wu Z. et al. The authors have successfully assessed every single query raised throughout the review process. The quality of the manuscript has been substantially ameliorated. I have no additional concerns regarding acceptance.